Adebrelimab plus chemo after HIFU for HR+/HER2- breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests a combination of a drug that helps your immune system (adebrelimab) plus chemotherapy, given after a focused ultrasound treatment (HIFU), for women with a specific type of breast cancer (HR+/HER2-) that has not spread beyond the breast or nearby lymph nodes. The goal is to see if this approach can shrink tumors before surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older.
- Your breast cancer is hormone receptor-positive (HR+) and HER2-negative.
- Your tumor is at least 3 cm (about 1.2 inches) in size and is a more aggressive type (grade 3).
- Your cancer has not spread to distant parts of the body.
- You are in good enough health to do daily activities (ECOG score 0-1).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of an immunotherapy drug (adebrelimab) plus chemotherapy before surgery for people with high-risk, hormone receptor-positive, HER2-negative breast cancer. The goal is to see if this approach can shrink tumors more effectively than chemotherapy alone.
This trial tests a combination of a new immunotherapy drug (adebrelimab) with a targeted pill (dalpiciclib) and standard hormone therapy for women with advanced hormone receptor positive, HER2 negative breast cancer. It may help patients who have not yet had certain prior treatments, aiming to slow the cancer's growth.
This trial tests a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) plus chemotherapy before surgery for people with a specific type of breast cancer (HR+/HER2-). The goal is to see if this treatment can shrink tumors and improve outcomes.
This trial tests giving chemotherapy, an immunotherapy drug (PD-1 inhibitor), and different types of radiation before surgery for people with a common type of breast cancer (HR+/HER2-). The goal is to see which radiation plan works best to shrink tumors.
This trial is testing a new treatment approach for patients with a certain type of breast cancer (HR+/HER2-). It combines radiation therapy with chemotherapy and an immunotherapy drug before the patient's main surgery, to see if it can shrink or eliminate the tumor more effectively.
This trial tests whether adding focused ultrasound (HIFU) and an immunotherapy drug (PD-1 inhibitor) before standard chemotherapy can improve outcomes for women with stage II or III triple-negative breast cancer (TNBC). It aims to find a more effective way to shrink tumors before surgery.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.